Gain Therapeutics (NASDAQ:GANX) Rating Reiterated by Chardan Capital

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reaffirmed by Chardan Capital in a report released on Friday, Benzinga reports. They presently have a $6.00 price objective on the stock.

A number of other equities analysts also recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a research note on Thursday, July 11th. Oppenheimer reaffirmed an “outperform” rating and set a $9.00 target price on shares of Gain Therapeutics in a research report on Tuesday, April 23rd.

Gain Therapeutics Trading Up 1.5 %

Shares of GANX traded up $0.01 during mid-day trading on Friday, reaching $0.98. 184,066 shares of the company’s stock traded hands, compared to its average volume of 209,677. Gain Therapeutics has a 12 month low of $0.92 and a 12 month high of $5.33. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.77 and a quick ratio of 2.77. The stock has a market cap of $17.72 million, a P/E ratio of -0.65 and a beta of 0.35. The stock’s 50-day moving average is $1.37 and its two-hundred day moving average is $2.87.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.08. Research analysts forecast that Gain Therapeutics will post -1.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Gain Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC raised its stake in Gain Therapeutics by 154.2% in the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after buying an additional 72,000 shares in the last quarter. Warberg Asset Management LLC purchased a new position in shares of Gain Therapeutics in the 2nd quarter valued at $66,000. Finally, Hohimer Wealth Management LLC purchased a new position in shares of Gain Therapeutics in the 2nd quarter valued at $422,000. 11.97% of the stock is currently owned by institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.